Shionogi Acquires 85 Percent Of Sciele
This article was originally published in PharmAsia News
Shionogi says its tender offer for control of U.S.-based Sciele Pharma has been met and it now has more than 85 percent of the shares. Shionogi extended its deadline for the remaining shareholders to sell their stock to Shionogi. The Japanese drug maker expects to pay about $1.5 billion for the medium-size Sciele. (Click here for more - a subscription may be required
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.